Logo
faq question Joey Med

Ribupatide's Phase 3 Results Just Landed in JAMA: What the Newest GLP-1 Contender Means for Weight Loss Patients in 2026

MD Telehealth Platform LLC DBA Joey Med is committed to protecting your health information in compliance with HIPAA regulations.
By Joey Med
5 min read
Published:
New JAMA results show ribupatide, a dual GLP-1/GIP injection, drove up to 19% weight loss in 48 weeks. What the newest obesity drug contender means for patients weighing treatment in 2026.

New JAMA results show ribupatide, a dual GLP-1/GIP injection, drove up to 19% weight loss in 48 weeks. What the newest obesity drug contender means for patients weighing treatment in 2026.

Overview

A new name just joined the short list of weight loss drugs with completed phase 3 results. On November 15, 2026, the full results of the GEMINI-1 trial of ribupatide — a once-weekly dual GLP-1/GIP injection developed by China's Hengrui Pharma and licensed to Boston-based Kailera Therapeutics — were published in JAMA, timed to ObesityWeek 2026. Patients on the highest dose lost 17.7% of their body weight on average in 48 weeks, and nearly half of them lost 20% or more.

If you are weighing treatment options today, ribupatide is not something you can get — it is not approved anywhere yet, and it is not available in the United States. But these results matter for anyone on, or considering, a GLP-1: they confirm that the pipeline behind semaglutide and tirzepatide keeps getting deeper, and more competition is one of the few forces that reliably pushes prices and access in patients' favor.

What the GEMINI-1 trial found

GEMINI-1 was a randomized, double-blind, placebo-controlled phase 3 trial that enrolled 567 adults at 55 sites in China, all with obesity or with overweight plus at least one weight-related health problem, and none with diabetes. Participants received once-weekly injections of ribupatide at 2 mg, 4 mg, or 6 mg, or placebo, for 48 weeks, alongside lifestyle counseling.

Average weight loss at 48 weeks:

The 2 mg dose produced 10.7% average weight loss, the 4 mg dose 16.4%, and the 6 mg dose 17.7%, compared with 1.4% for placebo. When researchers analyzed only the participants who stayed on treatment as planned, the 6 mg estimate rose to 19.2%. At the top dose, 44.4% of participants lost at least a fifth of their starting body weight — the kind of result that until recently was associated only with bariatric surgery.

Two details stand out for patients. First, weight loss had not clearly leveled off by week 48 at the higher doses, suggesting longer treatment could produce more. Second, about 90% of participants completed the full 48 weeks, which tells you the drug was tolerable enough for most people to stay on it.

Side effects: familiar GLP-1 territory

Ribupatide's safety profile looked much like the GLP-1 medications already in pharmacies. Gastrointestinal side effects — nausea, vomiting, diarrhea — were the most common, affecting 63.1% of participants at the 6 mg dose versus 23.1% on placebo. Most were mild to moderate and clustered around dose increases, the same pattern patients see with semaglutide and tirzepatide today.

Crucially, very few people quit over side effects: permanent discontinuation due to adverse events was between 0.7% and 1.4% across the ribupatide groups. No cases of medullary thyroid cancer or acute pancreatitis were reported. The study authors did flag one limitation — participants averaged just 34 years old, so the results may not generalize neatly to older adults.

Managing the GI window during dose escalation is a solvable problem on today's medications too; many providers pair treatment with prescription anti-nausea support during titration.

How it stacks up against tirzepatide

Ribupatide works the same way as tirzepatide (Zepbound): it activates both the GLP-1 and GIP receptors. The JAMA authors noted that tirzepatide 15 mg produced 17.5% weight loss at 52 weeks in its own China trial, SURMOUNT-CN — essentially the same ballpark as ribupatide's 17.7% at 48 weeks, though cross-trial comparisons are only descriptive, not head-to-head.

That is the practical takeaway: ribupatide does not appear to leapfrog what is already available to American patients. Tirzepatide is here now, with years of real-world safety data and FDA-regulated access through telehealth. What ribupatide adds is pressure — another credible dual-agonist moving toward market, alongside Novo Nordisk's CagriSema (awaiting an FDA decision), Lilly's oral orforglipron, and Pfizer's monthly berobenatide program.

When could it actually reach US patients?

Not soon. China's drug regulator accepted Hengrui's marketing application for chronic weight management in November 2025, so China will likely see approval first. For the rest of the world, Kailera is running a global phase 3 program (as KAI-9531) testing higher maintenance doses of 8 mg and 10 mg over at least 52 weeks — doses the company believes could push average weight loss past 20%. Those trials take years, which puts a realistic US arrival in the late 2020s at the earliest.

For patients, the message is patience about the pipeline but not about treatment. Obesity medicine is moving fast, and waiting years for a marginally different injection rarely beats starting an effective, available one now — especially since untreated obesity compounds risks to your heart, joints, liver, and metabolism in the meantime.

What this means if you're deciding on treatment now

The GEMINI-1 results reinforce three things worth discussing with a licensed provider. Dual GLP-1/GIP agonists are consistently the strongest class available, with trial results in the 16–20% range. Side effects across the class are predictable and front-loaded during titration, and they are manageable for the large majority of patients. And eligibility still matters: GLP-1 medications are prescribed based on BMI, health history, and screening for contraindications such as a personal or family history of medullary thyroid carcinoma or MEN 2 — which is why treatment should always start with a real clinical evaluation, not just an order form.

How to get started with JoeyMed

You don't need to wait for drugs that are still years from approval. JoeyMed's licensed providers prescribe today's proven GLP-1 treatments, including high-dose tirzepatide programs, after an online health evaluation that screens whether treatment is appropriate and safe for you. Plans include provider follow-up, dose titration guidance, and support for side effects along the way.

If you've been considering treatment, start with the basics: check your eligibility, review the options with a provider, and build a plan that fits your health history and budget. Visit JoeyMed Weight Loss to take the first step — no insurance required, and care is 100% online.

This article is for educational purposes only and is not medical advice. Treatment decisions should be made with a licensed healthcare provider.

Ribupatide's Phase 3 Results Just Landed in JAMA: What the Newest GLP-1 Contender Means for Weight Loss Patients in 2026 | Joey Med Blog – Joey Med | GLP-1 Telehealth Tampa FL